Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iranian 4 mg slow-release tolterodine capsule in overactive bladder syndrome
IRCT20231002059589N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tolterodine in overactive bladder (OAB), sponsored by Iran University of Medical Sciences. Started Apr 2025; status: completed.
02
Drugs
tolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20231002059589N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231002059589N1.